Blue Trust Inc. acquired a new stake in DiaMedica Therapeutics Inc. (NASDAQ:DMAC – Free Report) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 44,247 shares of the company’s stock, valued at approximately $185,000. Blue Trust Inc. owned 0.10% of DiaMedica Therapeutics at the end of the most recent reporting period.
Separately, Magnolia Capital Advisors LLC bought a new stake in DiaMedica Therapeutics in the 2nd quarter valued at about $87,000. Hedge funds and other institutional investors own 10.12% of the company’s stock.
DiaMedica Therapeutics Stock Performance
Shares of DMAC opened at $4.39 on Friday. The stock’s 50-day simple moving average is $4.18 and its 200 day simple moving average is $3.39. The stock has a market capitalization of $187.64 million, a price-to-earnings ratio of -7.84 and a beta of 1.48. DiaMedica Therapeutics Inc. has a 52-week low of $2.05 and a 52-week high of $4.95.
Wall Street Analysts Forecast Growth
A number of equities research analysts recently weighed in on DMAC shares. Oppenheimer restated an “outperform” rating and issued a $6.00 target price on shares of DiaMedica Therapeutics in a report on Friday, August 16th. HC Wainwright began coverage on DiaMedica Therapeutics in a report on Monday, October 7th. They issued a “buy” rating and a $7.00 target price on the stock.
Read Our Latest Stock Report on DiaMedica Therapeutics
DiaMedica Therapeutics Profile
DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.
Further Reading
- Five stocks we like better than DiaMedica Therapeutics
- Investing in Commodities: What Are They? How to Invest in Them
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- Stock Market Sectors: What Are They and How Many Are There?
- MarketBeat Week in Review – 10/21- 10/25
Want to see what other hedge funds are holding DMAC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DiaMedica Therapeutics Inc. (NASDAQ:DMAC – Free Report).
Receive News & Ratings for DiaMedica Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DiaMedica Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.